

**CECOG 6<sup>th</sup> Pancreas Cancer Academy, April 29 – 30, 2022, NH Hotel Vienna Airport**

Friday April 29<sup>th</sup>

---

**Joint Session:**

Welcome and Introduction 12:00-12:05

**C.Zielinski, G. Prager, P. Rivizzigno, I Rawicka**

How has the COVID-19 pandemic affected PAC patients (clinic visits, diagnosis, management of AE, telemedicine, visits by friends, immune response, etc.)

**tbd** 12:05-12:30

KEY Lecture: Personalized Treatment Approach by Molecular Profiling might Lead to Better Prognosis of mPDAC Patients.

**T. Golan** 12:30-13:00

**13:00- 14:00 Lunch Break**

**DOCTORS – WORKSTREAM**

a) **Resectable PDAC** Chair: G. Prager, T Macarulla

Patient Case 1: old patient PDAC, high risk, not fit for FOLFOXIRI, R1-resected  
Lukas Weiss 14:00-14:15

How to assess resectability? The surgeon's view  
**O. Strobel** 14:15-14:45

PANEL DISCUSSION on resection: methodological aspects and trial interpretation  
14:45-15:00

How to pick the individual neoadjuvant/adjuvant treatment concept in resectable PAC  
**E. van Cutsem** 15:00-15:30

PANEL DISCUSSION on adjuvant versus neoadjuvant for resectable PDAC 15:30 -15:45  
**15:45-16:15 Coffee Break**

b) **neoadjuvant PDAC** Chair: E. Van Cutsem, T. Golan

Patient Case 2: boarderline resectable PDAC  
Jakob Riedl 16:15-16:30

The DILEMMA 1: what is the best neoadjuvant treatment concept?  
**T. Macarulla** 16:30-17:00

DILEMMA 2: What to do with patients after secondary resection? (semiadj. Treatment? survivorship programs?)  
**H. Wasan** 17:00-17:30

PANEL: Q&A plus focus on the role of resection and systemic treatment 17:30-18:00

19:00 Networking Dinner

**Saturday April 30<sup>th</sup> 2022**

---

Joint Session: Meet the Expert 08:15-9:00

**9:00 – 9:30 Coffee Break**

**c) Advanced and Metastatic PDAC**

Chair: tbd

Patient Case 3: fit patient with mPDAC

H. Taghizadeh 9:30-9:45

Sequence Debate: gemcitabine/NP followed by FOLFIRINOX

**H. Wasan** 9:45-10:05

Sequence Debate: FOLFIRINOX followed by gemcitabine/NP

**J.Taieb** 10:05-10:25

Sequence Debate: Gem/NP followed by 5-FU/nal-IRI

**G. Prager** 10:25-10:45

PANELDISCUSSION: Is there a favorable sequence of treatment? 10:45-11:00

---

### **Joint session**

New ESMO Guidelines for Pancreatic Cancer: What is recommended when we treat PAC in 2022

**T. Conroy** 11:00-11:30

PANEL: Questions and Answers 11:30-11:45

**Closure, Disjourn** C.Zielinski, G. Prager, P. Rivizzigno, I Rawicka 11:45-12:00

## AGENDA NURSES /ADVOCACY

Friday April 29, 2022

### Joint Session:

Welcome and Introduction 12:00-12:05

**C.Zielinski, G. Prager, P. Rivizzigno, I Rawicka**

How has the COVID-19 pandemic affected PAC patients (clinic visits, diagnosis, management of AE, telemedicine, visits by friends, immune response, etc.)

**tbd** 12:05-12:30

KEY Lecture: Personalized Treatment Approach by Molecular Profiling might Lead to Better Prognosis of mPDAC Patients.

**T. Golan** 12:30-13:00

**13:00- 14:00 Lunch Break**

### Break out Room:

Pancreas cancer during covid – our experience in Liverpool – what we did different?

**P. Whelan** 14:00-14:20

Treatment options for pancreatic cancer – challenges and future perspectives

**I. Chen** 14:20 -14:50

Convivio: humanising care for pancreatic cancer patients

**D. Cafaro** 14:50-15:05

Social Cooking: the nutrition social dimension for pancreatic cancer patients

**A. Burini** 15:05-15:20

The Patients Reported Outcome, PRO. The PanDi project,

**P. Rivizzigno**

Paneldiscussion 15:20-15:35

**15:45-16:15 Coffee Break**

Prehabilitation in Pancreatic Cancer

**P Whelan** 16:15--16:35

### Session: My Story

Seth / L. Goodburn 16:35-16:55

Radek 16:55-17:15

Patrycja 17:15-17:35

Katarzyna 17:35-18:00

19:00 Networking Dinner

**Saturday April 30<sup>th</sup> 2022**

---

Joint Session: Meet the Expert 08:15-09:00

**09:00-09:30 Coffee Break**

The neoadjuvant approach: a 5 years survivor case  
**F. Santoro** 09:30-09:50

Grief in Patients diagnosed with cancer  
**N. Embel** 9:50-10:20

Medical Communication  
**D. Schmitt** 10:20-10:50

---

**Joint session**

New ESMO Guidelines for Pancreatic Cancer: What is recommended when we treat PAC in 2022  
**T. Conroy** 11:00-11:30

PANEL: Questions and Answers 11:30-11:45

**Closure, Disjourn** C.Zielinski, G. Prager, P. Rivizzigno, I Rawicka 11:45-12:00